Now I have all the data I need. Let me write the consolidated review.

---

## Summary

This paper evaluates small language models (up to 3B parameters) against large medically-adapted LLMs (7-8B) on clinical text summarization, and small VLMs against large medical VLMs on radiology report generation. Its main contributions are (1) a systematic scaling analysis across multiple model families, (2) a proposed "Collapse Analysis" framework measuring task adherence, hallucination rate, concept recall, and prompt robustness, and (3) identification of a ~1B parameter safety threshold. The headline finding is that after LoRA fine-tuning, small LMs can match or exceed large medical LMs on summarization metrics, while small VLMs continue to lag behind.

## Strengths

- **Broad and practically motivated evaluation across model families.** The paper tests SmolLM2 (135M–3B), Gemma-3 (270M–4B), Llama 3.2 (1B), Florence 2, and Qwen 2.5-VL against three large medical LLM baselines and two large VLM baselines (Table 1), providing a broader empirical picture than single-model studies. The practical motivation — can resource-constrained institutions deploy smaller models for clinical summarization — is timely and well-articulated.

- **Use of MEDCON as a domain-specific evaluation metric.** Going beyond surface-level n-gram metrics, the paper incorporates MEDCON (UMLS concept extraction) to measure clinical concept accuracy. This is a meaningful addition for the medical domain and gives the evaluation more clinical relevance than relying solely on BLEU/ROUGE/BERTScore.

- **The safety collapse pattern is empirically striking and practically relevant.** Even setting aside the undefined metrics (see Weaknesses), the raw data in Table 3 — hallucination rates jumping from 2-3% at 1.7B to 18.3% at 360M and 75% at 270M — reveals a non-linear degradation pattern that, if reproducible, would be genuinely useful for deployment decisions. The fine-grained dimension-level reporting (Prompt Robustness dropping before hallucination spikes) adds nuance.

- **Consistent experimental controls.** All runs use identical inference hyperparameters (temperature=0.3, top-k=3, top-p=0.9) and the same 250-sample test sets, improving cross-model comparability.

## Weaknesses

### Fatal
None.

### Major

- **The headline claim that small LMs "outperform large medical LMs" rests on an asymmetric comparison that is not sufficiently caveated.** The paper's central finding (Figure 3, Section 4) compares **LoRA-fine-tuned** small LMs against **zero-shot / in-context learning** large LMs (BioMistral, Med-LLaMA, OpenBioLLM). The large models were never fine-tuned on MeQSum data. Statements such as "After LoRA fine-tuning, all small LMs outperformed large LMs across every metric" (Section 4) and "small models not only reach but occasionally exceed the performance of much larger medical LLMs" (Abstract) are misleading without prominently acknowledging that the large models were not given the same adaptation opportunity.

The comparison *is* valid for a specific practical question ("Can I fine-tune a small model to beat a large medical model used off-the-shelf?"), but the paper frames it as testing whether model scale itself is a barrier. To support that broader claim, large models must also receive LoRA fine-tuning. This is the single most important experiment the paper lacks.

- **The "Collapse Analysis" metrics — a core contribution — are never operationally defined.** Table 3 reports Task Adherence, Hallucination Rate, Concept Recall, Prompt Robustness, and a composite Readiness Score, but the paper provides no specification of how any of these are computed:

  - Hallucination Rate: measured by MEDCON disagreement? Per-token? Per-sentence? Against what reference?
  - Task Adherence: exact format match or partial scoring? How are borderline cases handled?
  - Concept Recall: recall of UMLS concepts relative to the reference? How are synonyms and partial matches handled?
  - Prompt Robustness: quantified as variance across templates? Worst-case? The "five prompt templates" are mentioned but never enumerated.
  - Readiness Score: not defined at all, yet used to draw a safety threshold.

Without operational definitions, the collapse analysis — presented as a core contribution — is unverifiable and irreproducible. The ~1B safety threshold claim cannot be evaluated.

### Minor

- **No variance or confidence intervals reported.** All results are point estimates over 250 test samples without standard deviations, confidence intervals, or significance tests. Given the wide swings observed across model sizes (e.g., hallucination rates from 3.5% to 67.8% within the same family), it is unclear which differences are reliable. While single-run evaluation on a fixed test set is common practice, the paper's own emphasis on "prompt sensitivity" suggests variance is non-trivial and should be characterized.

- **The five prompt templates used for zero-shot evaluation are never enumerated.** The paper states "average zero-shot scores across five prompt templates" (Table 2 caption) but only shows one instruction. This hinders reproducibility, especially given the paper's finding that these models are prompt-sensitive.

- **The VLM comparison shares a similar asymmetry.** Small VLMs (Florence 2, Qwen 2.5-VL) are fine-tuned on 10,000 MIMIC-CXR pairs, while the large VLMs (Med-Flamingo, LLaVA-Med) were pre-trained on medical data but are not stated to have received equivalent fine-tuning on the same 10K subset. However, this weakness is less severe because (a) Med-Flamingo was pre-trained on the full MIMIC-CXR dataset, and (b) the paper's VLM finding ("small VLMs still lag") is cautious and actually supported by the data.

### Trivial
- Figure 2 caption does not explicitly state that the large models (Med-LLaMA, OpenBioLLM) were evaluated zero-shot, while LLaMA-3.2 received LoRA fine-tuning. This asymmetry should be stated directly in the caption.
- The cross-reference to Table 4 in the text appears as "Table ??", suggesting a compilation issue.

## Nice-to-Haves
- Fine-tune the large LLMs (BioMistral, Med-LLaMA, OpenBioLLM) with LoRA on MeQSum and compare all models under the same adaptation condition. This would cleanly test whether model scale confers an advantage when both small and large models receive equivalent fine-tuning.
- Report standard deviations over multiple random seeds or bootstrap confidence intervals for all metrics.
- Show qualitative examples of what "safety collapse" looks like across the collapse dimensions (not just one VLM example).
- Evaluate additional VLMs beyond the four tested to strengthen the VLM conclusions.

## Removed Points
These points were flagged by reviewers but are removed with justification:

- **"The citation of Aali et al. 2025 undermines the paper's central claim but is not addressed."** — The paper *does* address this tension (lines 84-87, explicitly acknowledging that physicians prefer larger models and positioning SLMs for context-grounded extraction, not open-ended reasoning). REMOVED (factually incorrect).
- **"Missing fine-tuning details (hyperparameters, epochs, train/validation split)."** — These details are likely in the appendix, which was stripped by the PDF parser. REMOVED (parser artifact).
- **"Missing appendix content / proofs."** — The note "Rest of paper (reference and Appendix) is removed" at line 429 is a parser artifact. REMOVED (parser artifact).
- **"Pure formatting / style nitpicks."** — Various minor presentation complaints. REMOVED (per instructions).

## Novel Insights
None beyond the paper's own contributions. The reviews surface the same tension that a reader would identify independently: the experimental design's asymmetric adaptation confound weakens the central claim, and the collapse analysis framework lacks the methodological specification needed to evaluate it. The reviews do not add a new conceptual lens that the paper itself does not already contain.

## Suggestions

1. **Reframe the central claim** to honestly reflect what was tested: "LoRA-fine-tuned small LMs can match or exceed zero-shot performance of larger medically-adapted LLMs on clinical summarization." If feasible, add the missing experiment where large models also receive LoRA fine-tuning — this is the cleanest way to answer the question posed by the title.

2. **Operationally define every dimension** of the collapse analysis (Task Adherence, Hallucination Rate, Concept Recall, Prompt Robustness, Readiness Score) with explicit formulas, thresholds, and handling of edge cases. Without this, the framework cannot be used or evaluated by other researchers.

3. **Add variance estimates** (at minimum, bootstrap confidence intervals over the 250 test samples) for all reported metrics, especially for the collapse analysis where small-model behavior is highly variable.

4. **Enumerate the five prompt templates** either in the main text or appendix, and specify how "Prompt Robustness" is computed from them.

5. **Tone down the abstract and introduction** to match what the evidence actually supports. The current framing overclaims relative to the experimental design.

## Score and Decision

### Calibration Anchors

| Path | Avg Score | Comparison |
|------|-----------|------------|
| `/home/wg25r/review_agent/human_reviews_2026/VKGTGGcwl6.md` (LLMs Get Lost) | **8.00** | Much stronger: clean methodology, thorough analysis, excellent writing. The current paper is substantially weaker. |
| `/home/wg25r/review_agent/human_reviews_2026/pXw0uRTSKT.md` (Record2Vec) | **6.00** | Stronger: well-defined pipeline, multi-site validation, clear contributions. The current paper has a more loosely scoped evaluation. |
| `/home/wg25r/review_agent/human_reviews_2026/tSy7OtONsg.md` (MENTAT) | **5.50** | Stronger: expert-annotated dataset, clear methodology, well-defined metrics. The current paper's undefined collapse metrics are a significant gap. |
| `/home/wg25r/review_agent/human_reviews_2026/cXFLLKCbsb.md` (CoT Fails) | **4.50** | Comparable: both have interesting large-scale findings weakened by methodological scope issues. The CoT paper was rejected. |
| `/home/wg25r/review_agent/human_reviews_2026/x4vwdjckZ6.md` (Contamination Sensitivity) | **4.00** | Comparable: both evaluate SLMs systematically but have design caveats that limit conclusions. |
| `/home/wg25r/review_agent/human_reviews_2026/B9i2B0IjRT.md` (Small to Large UQ) | **2.50** | Weaker: less coherent contribution and missing analysis. Current paper has clearer practical motivation. |
| `/home/wg25r/review_agent/human_reviews_2026/R9MzJjvzXv.md` (HealthSLM-Bench) | **1.50** | Much weaker: reuses existing datasets with minimal novel contribution. Current paper has more experimental originality. |

The paper addresses a practical and timely question, generates interesting empirical data across multiple model families, and identifies a qualitatively striking degradation pattern at sub-billion scales. However, two major issues prevent acceptance: (1) the headline finding comparing fine-tuned small models to zero-shot large models is misleadingly framed and the missing control experiment (LoRA on large models) would be needed to support the claim about model scale, and (2) the collapse analysis metrics — a core contribution — are never operationally defined, making the safety threshold claim unverifiable. These are fixable in a major revision but are not addressable in a rebuttal alone. Relative to the calibration anchors, the paper sits near the reject threshold: it has genuine strengths but suffers from methodological gaps that comparable accepted papers (Record2Vec at 6.0, MENTAT at 5.5) do not share.

**Score: 4.0**

MY FINAL SCORE: <pineapple>4.0</pineapple>
MY FINAL DECISION: <orange>Reject</orange>